Stocks Health care MRNA
NASDAQ · Health careModerna, Inc. (MRNA)
Moderna, Inc. brought in $2.2B of revenue over the twelve months to June 30, 2026, down 27.6% from a year earlier. It posted a net loss of $3.2B. In fiscal 2025 capital spending exceeded operating cash flow by $2.1B. At June 30, 2026 it held $1.7B in cash against $591M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on July 31, 2026.
Key facts about Moderna, Inc.
- Net worth
- Moderna, Inc. has a market value (market cap) of $90.3B at the latest share price, and shareholders' equity of $6.8B on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $1.9B (-39.9% year on year), with a net loss of $2.8B. Over the 12 months to June 30, 2026: revenue $2.2B, net loss $3.2B.
- Cash flow
- In fiscal 2025 operations used $1.9B of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on July 31, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Moderna, Inc.'s next report is expected around November 5, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Moderna, Inc. does
Moderna, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker MRNA.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $1.9B | -$2.8B | -$7.26 | -$2.1B |
| 2024 | $3.2B | -$3.6B | -$9.28 | -$4.1B |
| 2023 | $6.8B | -$4.7B | -$12.33 | -$3.8B |
| 2022 | $19.3B | $8.4B | $20.12 | $4.6B |
| 2021 | $18.5B | $12.2B | $28.29 | $13.3B |
| 2020 | $803M | -$747M | -$1.96 | $2B |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where MRNA ranks in Health care
Latest SEC filings
What Moderna, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 30, 2026Executive or director change8-KModerna appointed Juan Andres as Chief Operating Officer and announced the retirement of Dr. Jerh Collins.
- September 1, 2026
- August 12, 2026Passive stake (5% or more) SCHEDULE 13G
- August 6, 2026Passive stake changed SCHEDULE 13G/A
- July 31, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 2.1% to $145M versus the same quarter last year; diluted EPS -$1.97 versus -$2.13.
- July 31, 2026
- July 24, 2026Passive stake changed SCHEDULE 13G/A
- July 8, 2026
- May 11, 2026
- May 1, 2026Quarterly report 10-Q · period to March 31, 2026Revenue rose 260% to $389M versus the same quarter last year; diluted EPS -$3.40 versus -$2.52.
Insider trades
What the people running Moderna, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $45.6M worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 5, 2026 | Mock James MChief Financial Officer | Exercised options | 1,454 | - |
| October 5, 2026 | Mock James MChief Financial Officer | Shares withheld for tax | 704 | $133.8K |
| September 15, 2026 | Hoge StephenPresident | Exercised options | 76,452 | $933.5K |
| September 15, 2026 | Hoge StephenPresident | Soldpre-planned (10b5-1) | 40,281 | $5.9M |
| September 14, 2026 | Hoge StephenPresident | Exercised options | 76,453 | $933.5K |
| September 14, 2026 | Hoge StephenPresident | Soldpre-planned (10b5-1) | 40,294 | $5.8M |
| September 10, 2026 | Mock James MChief Financial Officer | Exercised options | 19,836 | $614.1K |
| September 10, 2026 | Mock James MChief Financial Officer | Soldpre-planned (10b5-1) | 19,836 | $2.7M |
Who owns MRNA
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Fmr LLC13G, passive with 1 related filers | 13.1% | August 6, 2026 |
| Vanguard Capital Management13G, passive | 6.53% | April 30, 2026 |
| Capital World Investors13G, passive | 5.6% | August 12, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 781 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Fmr LLC | 51,859,891 | +6,187,867 |
| BlackRock, Inc. | 30,599,409 | +963,533 |
| Vanguard Capital Management LLC | 23,208,792 | +336,334 |
| Capital World Investors | 22,276,996 | +3,579,302 |
| Baillie Gifford & Co | 18,206,778 | -1,779,098 |
| State Street Corp | 15,726,193 | +864,784 |
| Vanguard Portfolio Management LLC | 15,581,313 | -35,054 |
| Geode Capital Management, LLC | 9,710,335 | +275,203 |
| Morgan Stanley | 9,538,094 | +1,066,831 |
| Theleme Partners LLP | 8,057,571 | +9,326 |
| Two Sigma Investments, LP | 7,193,530 | -1,892,874 |
| Invesco Ltd. | 5,780,299 | +995,541 |
| Charles Schwab Investment Management Inc | 4,838,884 | +104,528 |
| Goldman Sachs Group Inc | 4,671,950 | -1,931,747 |
| Flagship Pioneering, LLC | 4,632,149 | 0 |
| UBS Group AG | 4,463,211 | +55,304 |
| Bnp Paribas Financial Markets | 4,377,120 | +59,901 |
| Norges Bank | 3,026,074 | new |
| Northern Trust Corp | 2,985,329 | +33,288 |
| Banque Pictet & Cie SA | 2,699,402 | -49,352 |
Insiders
11 insiders reported holding 8,244,831 shares in total, about $1.87B at the last price.
| Holder | Shares |
|---|---|
| Bancel StephaneChief Executive Officer, Director | 6,440,260 |
| Hoge StephenPresident | 1,562,029 |
| Klinger Shannon ThymeChief Legal Officer | 81,340 |
| Mock James MChief Financial Officer | 60,125 |
| Nader FrancoisDirector | 32,781 |
| Nabel Elizabeth GDirector | 19,317 |
| Horning SandraDirector | 18,585 |
| Hussain AbbasDirector | 12,066 |
| Rubenstein David M.Director | 9,643 |
| Tallett Elizabeth EDirector | 4,761 |
Questions about MRNA
What does Moderna, Inc. do?
Moderna, Inc. is a company in the Health care sector, listed on NASDAQ as MRNA. Its shares trade on NASDAQ under the ticker MRNA.
What is Moderna, Inc.'s net worth?
Moderna, Inc. has a market value (market cap) of $90.3B at the latest share price, and shareholders' equity of $6.8B on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Moderna, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $3.2B on revenue of $2.2B.
How much revenue does Moderna, Inc. make?
Over the twelve months to June 30, 2026 Moderna, Inc. reported revenue of $2.2B. That is 27.6% less than a year earlier.
When did Moderna, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on July 31, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the planned insider sale from October 14, 2026.
When is Moderna, Inc.'s next earnings report?
Moderna, Inc.'s next report is expected around November 5, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare MRNA with
Follow MRNA
Get an email when Moderna, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Moderna, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.